Atheronova, Inc. (AHROD: OTCQB) | AtheroNova Announces Q1

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Atheronova, Inc. (AHROD: OTCQB) | AtheroNova Announces Q1 2014 Financial Results/Highlights

IRVINE, Calif., May 19, 2014 (GLOBE NEWSWIRE) -- AtheroNova Inc. (OTCBB:AHROD), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced its financial results for the fiscal quarter ended March 31, 2014 and provided a corporate update on operations and progress on lead candidate AHRO-001.

Q1 2014 Financial Results:

  • Total operating expenses for the 3 months ended March 31, 2013 were $2.1 million, compared to $1.5 million in the same period of 2013.
  • Net loss attributable to common stockholders for the 3 months ended March 31, 2014 was $6.1 million, or $1.46 per basic and diluted share. This compares to a net loss of $1.6 million, or $0.43 per basic and diluted share in the same period of 2013.
  • As of March 31, 2014, the Company had cash & cash equivalents of approximately $1.1 million.

Q1 2014 Corporate Highlights:

  • Completed senior secured convertible note and warrant placement of $1.9 million in February 2014.
  • Announced positive Phase 1 safety and tolerability results from one clinical study of AHRO-001 in healthy volunteers with mild dyslipidemia.
  • Submitted protocol for initiation of next AHRO-001 clinical study to Russian Ministry of Healthcare.
  • Received second issued patent (number 8,697,633) covering an additional bile acid compound in the treatment of atherosclerotic plaque.
  • Strengthened management team with the addition of Dr. Randolph Johnson as Chief Operating Officer.

"We will continue to broaden our clinical experience with the next planned clinical trial currently under final review by the Russian regulatory agency," said Thomas Gardner, AtheroNova's Chairman and Chief Executive Officer.  "We continue to execute on the CardioNova program as well as expansion of the U.S. based clinical and pre-clinical development programs in anticipation of filing our Investigational New Drug (IND) application for AHRO-001 with the FDA later this year. The addition of Dr. Randolph Johnson as COO will accelerate not only our clinical development programs, but also will increase our drug discovery program as we further develop proprietary molecules within our family of compounds. Our latest patent issuance broadens our platform and opens up opportunities for an accelerated path to market for this new intellectual property. All in all, Q1 was lean on expenses and heavy on accomplishments. Our core operating cash usage increased modestly from $0.8 million in the first 3 months of 2013 to $1.0 million in the first three months of 2014 and we will continue this conservative cash management in future periods. I'm very proud of the AtheroNova team."

About AtheroNova

AtheroNova Inc. is a biotechnology company focused on the discovery, research, development and licensing of novel compounds to safely reduce or regress atherosclerotic plaque deposits and improve lipid profiles in humans. In addition to its lead compound AHRO-001, AtheroNova plans to develop multiple applications for its patented and patents-pending therapies in market sectors that include: Cardiovascular Disease, Stroke and Peripheral Artery Disease, all of which have been linked to atherosclerosis. Atherosclerosis and its related pharmaceutical expenses for these indications cost consumers more than $41 billion annually in the United States alone. For more information, please visit www.AtheroNova.com .

Forward-Looking Statements

This news release includes "forward-looking statements". These statements are based upon the current beliefs and expectations of AtheroNova's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; AtheroNova's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of AtheroNova's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. Examples of forward-looking statements in this release include statements related to data produced by the subject clinical study and the Company's clinical development plan.

AtheroNova undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in AtheroNova's 2013 Annual Report on Form 10-K and the Company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site ( www.sec.gov ).

AtheroNova Inc.
Statement of Operations
(In thousands, except per share amounts)
  3 months ended
  March 31,
  2014 2013
Research and development $1,549 $435
General and administrative 515 1,068
Total operating expenses 2,064 1,503
     
Interest expense 482 121
Private placement costs 3,340 --
Non-cash derivative (gains)/loss, net 245 --
Other (income)/expense -- (1)
Income taxes 2 1
Net loss attributable to holders of Common Stock ($6,133) ($1,624)
Net basic and diluted loss per share $(1.46) $(0.43)
Weighted average number of shares used in computing basic and diluted net loss per share* 4,212,375 3,798,337
 
*Reflects 1-for-10 reverse stock split effective on April 22, 2014
 
 
AtheroNova Inc.
Balance Sheet Data
(In thousands)
  March 31, December 31,
ASSETS 2013 2013
Current assets:    
Cash and cash equivalents $ 1,143 $ 266
Prepaid expenses 62 23
Total current assets 1,205 289
Equipment, Net 6 7
Deposits and other assets 13  13
Total assets $ 1,224 $ 309
     
LIABILITIES AND SHAREHOLDERS' DEFICIENCY    
Current liabilities:    
Accounts payable and accrued expenses $ 816 $ 812
Interest payable 87 76
Derivative liabilities 4,833 --
Current portion of Senior secured notes, net of discount 417 390
Total Current liabilities 6,153 1,278
Senior secured notes, net of discount 372 363
Research and development costs payable in common stock -- 1,171
Shareholders' equity (deficiency):    
Common stock -- --
Additional paid-in capital 20,709 19,527
Common stock issuable 2,153 --
Deficit accumulated during the development stage (28,163) (22,030)
Total shareholders' deficiency (5,301) (2,503)
     
Total liabilities and shareholders' deficiency $ 1,224 $ 309
 CONTACT: Company Contact:           Thomas Gardner, CEO           Tel: (949) 476-1100           or           Mark Selawski, CFO           Tel: (949) 476-1100                      Investor Contact:           Andrew McDonald           LifeSci Advisors LLC           Tel: (646) 597-6987 
Scroll down for more posts ▼

Top 10 Most Recent News Articles

EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 718

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 97

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 302

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 158

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 410

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 262

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 203

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 216

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 385

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading

Top 5 Most Recently Viewed Articles

Blend's AWS Financial Services Competency Enhances Innovations

Updated Category News Views 152

Blend Takes a Major Stride with AWS Financial Services Competency Exciting news emerges from Blend as the company secures a crucial recognition in the cloud technology arena. They've recently achieved the prestigious AWS Financial Services Competency badge, a testament to their outstanding expertise and remarkable track record in delivering innovative, secure, and...

Continue Reading
The Upcoming Surge of Last Mile Delivery Market Growth

Updated Category News Views 289

Overview of the Last Mile Delivery Market Growth The Last Mile Delivery market is poised for significant growth in the coming years, projected to rise by USD 51.1 billion from 2025 to 2029. This increase is primarily driven by the expanding global e-commerce sector and the integration of advanced technologies, including AI, which are transforming logistical operations....

Continue Reading
Tide Rock Expands Its Precision Machining Horizons Through Acquisitions

Updated Category News Views 326

Tide Rock Expands Its Precision Machining Horizons Tide Rock has taken a significant leap forward in the field of advanced precision machining through its recent acquisitions. By acquiring Precision Waterjet & Laser, now known as Precision Advanced Machining, located in Anaheim, California, and Made in America Manufacturing based in Buda, Texas, Tide Rock is enhancing its...

Continue Reading
Novavax Revises Projections, Anticipates Robust Nuvaxovid Demand

Updated Category News Views 149

Novavax Reports Strong Second Quarter Results Recently, Novavax Inc. reported impressive sales of $239.24 million for the second quarter of 2025, marking a significant shift from $415 million during the same period in the previous year. This figure exceeded the Wall Street consensus expectations, which estimated sales at $156.29 million. Such growth highlights Novavax's...

Continue Reading
Insights into Novartis' Cosentyx and GCAptAIN Study Findings

Updated Category News Views 219

Novartis' Groundbreaking Updates on Cosentyx in GCAptAIN Study Novartis has recently provided significant updates regarding the Phase III GCAptAIN study, focusing on the efficacy of Cosentyx (secukinumab) for patients suffering from giant cell arteritis (GCA). This condition, predominantly affecting older adults, poses a risk of severe complications if not managed...

Continue Reading